Personalized Risk Feedback for Lung Cancer Screening and Smoking Cessation
(PRECISE Trial)

Recruiting in Palo Alto (17 mi)

Overseen byAlex Ramsey, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Washington University School of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests the effects of two versions of RiskProfile, a clinically-informed and a genetically-informed version of a patient-specific risk feedback tool, in comparison to usual care, on lung cancer screening and tobacco treatment. The trial assesses the multilevel effects of these precision risk feedback tools on the likelihood of clinicians to order lung cancer screening and tobacco treatment and of their patients to utilize these cancer prevention interventions.

Research Team

Li-Shiun Chen, M.D., MPH, ScD

Principal Investigator

Washington University School of Medicine

Alex Ramsey, PhD

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for current smokers or those who quit within the last 15 years, aged 50-80, with a history of heavy smoking (≥20 pack-years), and have never been screened for lung cancer. Participants must be patients of clinicians in the study's clinics and speak English. Those already scheduled for lung cancer screening, diagnosed with lung cancer, or unable to provide a DNA sample are excluded.

Inclusion Criteria

Primary care clinician with active caseload in participating clinics

You are currently smoking or stopped smoking within the last 15 years.

You have not been screened for lung cancer before.

See 4 more

Exclusion Criteria

Current order placed for lung cancer screening

I have been diagnosed with lung cancer.

The analysis of your DNA sample was not successful.

Treatment Details

Interventions

RiskProfile-Clin (Behavioral Intervention)
RiskProfile-Gen (Behavioral Intervention)
Usual Care (Behavioral Intervention)

Trial OverviewThe trial examines two personalized risk feedback tools—clinically-informed (RiskProfile-Clin) and genetically-informed (RiskProfile-Gen)—against standard care. It aims to see if these tools affect how often doctors order lung cancer screenings/smoking cessation treatments and if their patients follow through.

Participant Groups

3Treatment groups

Experimental Treatment

Active Control

Group I: RiskProfile-GenExperimental Treatment1 Intervention

RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.

Group II: RiskProfile-ClinExperimental Treatment1 Intervention

RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.

Group III: Usual CareActive Control1 Intervention

Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.